Skip to main content

Table 1 Patient’s laboratory results at different time points

From: A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report

Time Haemoglobin level
(reference range 11.5–14.5 g/dL)
Platelet count
(reference range 150–400 × 109/L)
C3 level
(reference range 0.80–1.60 g/L)
Protein excretion in first-morning urine dipstick
(reference range < 30 mg/dL)
At time of diagnosis and eculizumab initiation 5.9 23 0.55 > 400
1 month after diagnosis 9 169 0.91 100
6 months on eculizumab every 2 weeks 11.8 543 NA 100
1 month after increasing the eculizumab interval to every 3 weeks 12.2 494 0.78 300
4 months after increasing the eculizumab interval to every 3 weeks 11.1 462 NA 300
1 month after resuming eculizumab every 2 weeks 12.2 491 NA 100
4 months after resuming eculizumab every 2 weeks 11 641 NA 100